Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
Immune Globulin Subcutaneous 16.5% in the Treatment of Primary Immunodeficiency: A Two-Year Multicenter Analysis
Presented at AAAAI 2024 Authors: Richard F. Herrscher, MD, FACAAI Jeffrey W. Langford, MD, AE-C Precious A. Anyanwu, PharmD, PhD Lucinda J. Van Anglen, PharmD View...
Early Experience with a Simple Administration of a Novel Fecal Microbiome Replacement for Prevention of Recurrent Clostridioides difficile
Presented at IDWeek 2023 Authors: Richard L. Hengel MD Sujatha Krishan, MD Jonathan A. Rosenberg, MD Timothy E. Ritter, MD Kathy A. Baker Ph.D., APRN Lucinda J. Van Anglen, BS, PharmD Amy Guo, PhD Mielad Moosapanah, PharmD Min Yang, MD, PhD Kevin W. Garey, PharmD...
Real-World Outcomes with Subcutaneous Immunoglobulin 16.5% in the Treatment of Primary Immunodeficiency
Presented at IgNS 2023 Authors: Lucinda J. Van Anglen, PharmD Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Precious A. Anyanwu, PharmD, PhD View...
Real-World Outcomes After Switching to Immune Globulin Subcutaneous 16.5% In Patients with Primary Humoral Immunodeficiency: A 3-Year Study
Presented at AAAAI 2023 Authors: Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Dawn N. Kim-Romo, PharmD, PhD, MS Lucinda J. Van Anglen, PharmD View...
Treatment With Intravenous Immune Globulin 10% In A Real-World Outpatient Setting
Presented at AAAAI 2023 Authors: Richard F. Herrscher, MD, FACAAI Kevin Rosenbach, MD Quyen Luu, MD Dawn N. Kim-Romo, PharmD, PhD, MS Lucinda J. Van Anglen, PharmD View...
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics
Presented at NLA 2023 Authors: Christie M. Ballantyne, MD Tyler J. Varisco Timothy E. Graham, MD Bruce J. Iteld, MD Harvey Serota, MD Sean McElligott Xiaoli Niu, PhD Lucinda J. Van Anglen, PharmD View...
Long-Term Outcomes with Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency
Presented at ACAAI 2023 Authors: Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Precious A. Anyanwu, PharmD, PhD Lucinda J. Van Anglen, PharmD View...
Real-World Use of Inclisiran in Outpatient Physician Clinics
Presented at ADA 2023 Authors: Timothy E. Graham, MD Tyler J. Varisco PharmD, PhD Christie M. Ballantyne, MD Bruce J. Iteld, MD Harvey Serota, MD Sean McElligott, MS Xiaoli Niu, PhD Lucinda J. Van Anglen, PharmD View...
Epstein-Barr Virus Associated Ulcers in a Patient with Ulcerative Colitis Taking Vedolizumab: A Case Report
Presented at ACG 2023 Authors: Christopher Fernandes, BSc Christine Catinis, MS, MD Precious Anyanwu, PharmD, PhD, Timothy E Ritter, MD View Poster View...
Ileocecal Stricture as a Manifestation of Disseminated Histoplasmosis in an Immunosuppressed Patient: A Case Report
Presented at ACG 2023 Authors: Christine Catinis MD, Maya Sarihan MD, Abdullah Aleem MD, Parvir Aujla MD, Mary E Howerton, Christopher C Fernandes, Precious A. Anyanwu, PharmD, PhD, Timothy E Ritter, MD View Poster View...
Real-World Immune Globulin Subcutaneous 16.5% Use in Treatment-Naïve Patients with Primary Immunodeficiency
Presented at IgNS 2022 Authors: Lucinda J. Van Anglen, PharmD Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Dawn N. Kim-Romo, PharmD, PhD, MS View...
Real-World Evaluation of Immune Globulin Intravenous 10% in the Treatment of Primary Immunodeficiency
Presented at IgNS 2022 Authors: Lucinda J. Van Anglen, PharmD Dawn N. Kim-Romo, PharmD, PhD, MS View...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.